参考文献/References:
[1]陈荣, 刘光辉, 周总光. 外周血microrna作为肿瘤标志物的研究进展[j]. 中国普外基础与临床杂志, 2012, 19(9):1020-1023.
[2]许建, 武治印, 于典科. 血清microrna在肿瘤诊断和预后评估中的应用[j]. 科学通报, 2010, 55(1):2-6.
[3]赵士艳, 聂秀利, 杨莉, 等. 肿瘤标志物研究进展[j]. 标记免疫分析与临床, 2011, 18(1):59-62.
[4]pujol jl, grenier j, parrat e, et al. cytokeratins as serum markers in lung cancer:a comparison of cyfra 21-1 and tps[j]. am j respir crit care med, 1996, 154(3 pt 1):725-733.
[5]yang x, wang d, yang z, et al. cea is an independent prognostic indicator that is associated with reduced survival and liver metastases in sclc[j]. cell biochem biophys, 2011, 59(2):113-119.
[6]阿合力·那斯肉拉, 巴尔夏古丽·扎比胡拉, 穆朝东. 血清 cea cyfar21-1 scc ca125 水平对晚期非小细胞肺癌放疗疗效的评估价值[j]. 实用癌症杂志, 2014, 29(9):1055-1057.
[7]molina r, filella x, augé jm, et al. tumor markers(cea, ca 125, cyfra 21-1, scc and nse)in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. comparison with the main clinical and pathological prognostic factors[j]. tumour biol, 2003, 24(4):209-218.
[8]王颖轶, 陈书长. 肿瘤标志物对晚期非小细胞肺癌患者放疗疗效的评估价值[j]. 实用癌症杂志, 2014, 29(1):23-25.
[9]吴艳涛, 兰潇. 血清肿瘤标志物对晚期原发性肺癌老年患者放疗疗效的评估价值[j]. 癌症进展, 2015, 13(2):209-212.
[10]郭健, 高志斌, 贺少枫, 等. 肿瘤标志物与晚期肺癌立体定向放疗疗效的相关性[j]. 临床肺科杂志, 2012, 17(11):2048-2050.
[11]王杰, 胡学宁, 陈大兴. 血清肿瘤标志物对晚期nsclc放疗疗效的评估价值[j]. 实用癌症杂志, 2014, 29(6):626-628.
[12]闫云宇, 翟福山, 王安峰, 等. 图像引导下大分割放疗对局部晚期非小细胞肺癌患者血清肿瘤标志物及转移侵袭相关指标的影响研究[j]. 中国医药导报, 2013, 10(32):42-44, 47.
[13]wei x, xu h, kufe d. muc1 oncoprotein stabilizes and activates estrogen receptor alpha[j]. mol cell, 2006, 21(2):295-305.
[14]bast rc jr, ravdin p, hayes df, et al. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer:clinical practice guidelines of the american society of clinical oncology[j]. j clin oncol, 2001, 19(6):1865-1878.
[15]鄢盛恺, ulf-h?覽kan s, rolf l, et al. 美国临床生化科学院检验医学实践指南:睾丸、前列腺、结直肠、乳腺及卵巢癌肿瘤标志物的应用[j]. 临床检验杂志, 2012, 30(2):116-160.
[16]陶冀, 游廉, 王锡山. 乳腺癌肿瘤标志物cea、ca15-3表达水平的临床意义[j]. 中国肿瘤临床, 2005, 32(13):751-754.
[17]高寒, 姜军, 杨新华, 等. 5种血清标志物的不同组合对提高乳腺癌诊断的意义[j]. 第三军医大学学报, 2007, 39(12):1255-1257.
[18]崔红霞, 韩存芝, 杜丽莉, 等. 肿瘤标志物在监测乳腺癌患者复发转移中的意义[j]. 中国循证医学杂志, 2008, 8(10):842-845.
[19]李彦格, 刘会芝, 薛晓英, 等. 恶性肿瘤放疗前后血中肿瘤标志物含量的变化[j]. 河北医药, 2009, 31(8):970-971.
[20]kievit j. follow-up of patients with colorectal cancer:numbers needed to test and treat[j]. eur j cancer, 2002, 38(7):986-999.
[21]kitsuki h, katano m, morisaki t, et al. cea-mediated homotypic aggregation of human colorectal carcinoma cells in a malignant effusion[j]. cancer lett, 1995, 88(1):7-13.
[22]王晶晶, 陈康, 徐万菊. 直肠癌患者手术前后血清ca199和ca242水平测定及预后评价[j]. 中华肿瘤防治杂志, 2009, 16(21):1667-1668.
[23]周伟, 黄林平, 韦佳明, 等. cea、ca19-9和ca242动态变化评判82例结直肠癌治疗效果及预后分析[j]. 肿瘤学杂志, 2009, 15(6):556-558.
[24]魏瑞, 张阳德, 何剪太, 等. 直肠癌的三维适形放疗及多肿瘤标志物的变化[j]. 中国肿瘤临床, 2007, 34(16):913-916.
[25]hong sy, cho ds, kim si, et al. prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer[j]. korean j urol, 2012, 53(9):607-613.
[26]lumen n, fonteyne v, de meerleert g, et al. population screening for prostate cancer:an overview of available studies and meta-analysis[j]. int j urol, 2012, 19(2):100-108.
[27]左其明, 周占松. 前列腺癌肿瘤标志物的研究进展[j]. 医学综述, 2013, 19(24):4456-4458.
[28]rafferty b, rigsby p, rose m, et al. reference reagents for prostate-specific antigen(psa):establishment of the first international standards for free psa and psa(90∶10)[j]. clin chem, 2000, 46(9):1310-1317.
[29]schaefer u, micke o, willich n. prostate-specific antigen(psa)and radiotherapy in locally confined prostate cancer[j]. anticancer res, 1999, 19(4a):2645-2648.
[30]kita y, imamura m, mizowaki t, et al. late recurrence of nonseminomatous germ cell tumor successfully treated with intensity-modulated radiation therapy[j]. jpn j clin oncol, 2013, 43(8):835-837.